Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study

Basit Öğe Kaydı
dc.contributor.authorWang, Jie
dc.contributor.authorMa, Zhiyong
dc.contributor.authorHuang, Dingzhi
dc.contributor.authorFan, Yun
dc.contributor.authorYu, Xinmin
dc.contributor.authorHu, Sheng
dc.contributor.authorWang, Ziping
dc.date.accessioned2025-05-10T19:27:45Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 08-13, 2022 -- New Orleans, LA
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Assoc Canc Res
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.issue12
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7063
dc.identifier.volume82
dc.identifier.wosWOS:000892509500076
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAmer Assoc Cancer Research
dc.relation.ispartofCancer Research
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleTislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu